INNOVATIVE IDEAS ON THE WAY TO MARKET.

13/02/2025

Cardior co-founder and RNA expert Prof. Thomas Thum joins board of MAxL team RNATICS

Biotech start-up RNATICS strengthens its management team with Prof. Dr. Thomas Thum. As an internationally recognized expert in the field of RNA medicine, he will provide the company with strategic and scientific support. RNATICS is part of BioM's MAxL start-up incubator and develops innovative RNA therapeutics against inflammatory lung diseases.

The Martinsried-based biotech start-up RNATICS has appointed Prof. Dr. Thomas Thum to its Board of Directors. With more than 20 years of experience in the field of RNA therapeutics and as co-founder of Cardior Pharmaceuticals GmbH, Thum has made a significant contribution to the development of innovative RNA-based approaches. In addition to his role as Director of the Instituts für Molekulare und Translationale Therapiestrategien (IMTTS) at the Hannover Medical School... [read more]


01/2025

Enzymatic solutions for a circular economy - Twogee Biotech moved into MAxL

A world where chemical and material production is fully integrated into a sustainable circular economy, contributing to environmental preservation and social well-being. That is the vision of the latest addition to the MAxL: start-up Twogee Biotech... [read more]


10/2024

A new team joined MAxL at the end of 2024: OmicsDiscoveries

The vision of OmicsDiscoveries is to facilitate and accelerate genetic testing. Through their advanced machine learning-based analysis of RNA sequencing data, they transform raw data into human-readable reports, supporting translational research. We provide an interactive analysis platform that integrates genetic variants, database annotations... [read more]


10/2024

FLASH Tissue Diagnostics is the latest addition to MAxL

Our latest addition to the MAxL is FLASH Tissue Diagnostics (FLASH TD). FLASH TD developed the technologically disruptive FLASH method, in which the entire lymph node is made transparent while its native 3D structure is preserved. This enables the quantitative detection of tumor cells in the entire... [read more]


08/2024

Leopard Biosciences joins MAxL to further develop innovative Point-of-Care Diagnostics

Current molecular diagnostics tests are too complex and too expensive to be used at the Point-of-Care. Leopard Biosciences is democratizing molecular diagnostics by developing instrument-free, easy-to-use, multiplex point-of-care tests with short turnaround time and low cost of goods. Leopard tests combine the simplicity... [read more]


07/2024

RNATICS is the first tenant at MAxL

We welcome the first tenant in the “Munich Accelerator Life Sciences & Medicine” (MAxL) in Martinsried. RNATICS GmbH is a young, innovative biotech company developing targeted nucleic acid therapies against inflammatory lung diseases applied via inhalation. The drugs are... [read more]


06/26/2024

MAxL in Martinsried: BioM opens new start-up incubator - 8.5 million euros for innovative start-up teams to strengthen biotechnology in Bavaria

BioM Biotech Cluster Development GmbH together with State Secretary Tobias Gotthardt has officially opened the start-up incubator "Munich Accelerator Life Sciences & Medicine" (MAxL) in Martinsried. MAxL supports innovative founders in the field of life sciences and medicine... [read more]